Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

140
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
140
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

126
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
126

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Simultaneous resection of pancreatic cancer and liver metastases following total neoadjuvant therapy: A case series and analysis of the National Cancer Database.

Annals of hepato-biliary-pancreatic surgery·2026
Same author

An Accessible Python Framework for Real-Time Magnetic Tweezers Microscope Control and Image Processing.

bioRxiv : the preprint server for biology·2025
Same author

Epigenetic Modulation, Intratumoral Microbiome, and Immunity in Early-Onset Colorectal Cancer.

Cancer research communications·2025
Same author

Epigenetic Modulation, Intra-tumoral Microbiome and Immunity in Early Onset Colorectal Cancer.

bioRxiv : the preprint server for biology·2025
Same author

Riluzole in Combination with mFOLFOX6 and Bevacizumab in Treating Patients with Metastatic Colorectal Cancer: A Phase I Clinical Trial.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025
Same author

Proteomic Profiling of Medullary Thyroid Cancer Identifies CAPN1 as a Key Regulator of NF1 and RET Fueled Growth.

Thyroid : official journal of the American Thyroid Association·2025
Same journal

Editor's Note: Akt/mTOR Counteract the Antitumor Activities of Cixutumumab, an Anti-Insulin-like Growth Factor I Receptor Monoclonal Antibody.

Molecular cancer therapeutics·2026
Same journal

Preclinical Comparison of Two CD3xB7H4 Bispecific Antibodies for Solid Tumor Therapy Reveals CD3 Affinity-Dependent Potency and Tolerability Tradeoffs.

Molecular cancer therapeutics·2026
Same journal

RIG-I-targeted immunotherapy synergizes with immune checkpoint inhibition in a hepatocellular carcinoma model.

Molecular cancer therapeutics·2026
Same journal

Improving Immune Checkpoint Blockade Efficacy in Melanoma Brain Metastases through Myddosomal inhibition with Emavusertib.

Molecular cancer therapeutics·2026
Same journal

Anti-Tumor Activity of Cdk2/9 Inhibitor Fadraciclib in an In Vivo Model of Temozolomide Refractory Neuroblastoma.

Molecular cancer therapeutics·2026
Same journal

Concurrent inhibition of ICMT and RAF/MEK suppresses RAC1P29S-driven MAPK-pathway-inhibitor resistance in BRAFV600E melanoma by regulating TAZ activity.

Molecular cancer therapeutics·2026
查看所有相关文章

相关实验视频

Updated: Jun 11, 2025

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer
06:24

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer

Published on: October 13, 2023

826

利卢通过激活结肠直肠癌中的cGAS/STING信号来增强抗PD-1的有效性

Beiyuan Liang1, Misbah Khan1, Hayden Storts1

  • 1Department of Cancer Biology and Genetics, James Comprehensive Cancer Center, Wexner Medical Center, The Ohio State University, Columbus, Ohio.

Molecular cancer therapeutics
|October 9, 2024
PubMed
概括
此摘要是机器生成的。

利卢是一种ALS药物,通过激活结肠癌细胞中的cGAS/STING通路来增强抗瘤CD8+T细胞. 这提高了抗PD-1疗法的有效性,为结直肠癌治疗提供了新的希望.

更多相关视频

Portal Vein Injection of Colorectal Cancer Organoids to Study the Liver Metastasis Stroma
07:59

Portal Vein Injection of Colorectal Cancer Organoids to Study the Liver Metastasis Stroma

Published on: September 3, 2021

6.3K
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

13.6K

相关实验视频

Last Updated: Jun 11, 2025

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer
06:24

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer

Published on: October 13, 2023

826
Portal Vein Injection of Colorectal Cancer Organoids to Study the Liver Metastasis Stroma
07:59

Portal Vein Injection of Colorectal Cancer Organoids to Study the Liver Metastasis Stroma

Published on: September 3, 2021

6.3K
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

13.6K

科学领域:

  • 在瘤学瘤学.
  • 免疫学 免疫学 免疫学
  • 药理学 药理学是指药理学的学科.

背景情况:

  • 结肠直肠癌是癌症死亡的主要原因之一.
  • 目前的免疫疗法,如抗PD-1/PD-L1,在许多患者中有效性有限.
  • 需要新的治疗策略来改善结直肠癌治疗结果.

研究的目的:

  • 为了研究riluzole在结肠直肠癌中的抗瘤作用.
  • 为了阐明瑞卢的作用的潜在分子机制.
  • 评估riluzole与免疫检查点抑制剂结合的潜力.

主要方法:

  • 利用了结肠癌的同基因免疫竞争性小鼠模型.
  • 给定了riluzole,并评估了瘤生长和瘤内CD8+T细胞透.
  • 研究了cGAS/STING通路和ATM在利鲁的作用机制中的作用.
  • 结合利卢与抗PD-1疗法,以评估协同效应.

主要成果:

  • 利鲁抑制了瘤生长,并以 CD8+ T 细胞依赖的方式增加了瘤内 CD8+ T 细胞.
  • 利鲁在结肠癌细胞中激活了cGAS/STING通路,上调IFNβ和CXCL10.
  • 瑞卢的作用取决于cGAS/STING激活,并涉及ATM介导的DNA损伤反应.
  • 与利卢和抗PD-1的联合治疗与单一药物相比,显示出更强的抗瘤疗效.

结论:

  • 利鲁可激活瘤细胞内在的cGAS/STING天生的免疫反应.
  • 利卢可增强CD8+T细胞的透和瘤抑制.
  • 利鲁作为抗PD-1/PD-L1治疗结直肠癌的敏感剂具有前景.